A conference that includes all types of neuroendocrine tumor patients including mid-gut ‘noids, Lungnoids, P-Net patients and more. get ready for another fantastic lineup featuring over 20 world class NET experts presenting the information you need to make informed decisions about your health. Some of the topics are brand-new and just published, sprinkled in with advice from the experts on the top issues faced by NET patients. Topics that will be covered welcome an audience of all levels,
Summary: Robert Fine, MD, reported at a press conference held in advance of the 2014 Gastrointestinal Cancers Symposium (GICS), that the chemotherapy combination of capecitabine plus temozolomide either stalled disease progression or shrank tumors in 97% of patients whose disease had worsened after standard high-dose octreotide. Read the full story at Medscape. You can sign up for a free account to access the full article.